Market Overview:
The global fulvestrant market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The growth in the market can be attributed to factors such as rising prevalence of breast cancer, increasing awareness about available treatment options, and growing demand for targeted therapies. By type, the market is segmented into 1 injection/box and 2 injection/box. By application, the market is segmented into hospital, clinic, drug center, and other. The hospital segment accounted for the largest share of the global fulvestrant market in 2017. Geographically, North America dominates the global fulvestrant market followed by Europe and Asia Pacific.
Product Definition:
Fulvestrant (ICI 182,780) is a selective estrogen receptor modulator (SERM). It is approved in the United States for the treatment of postmenopausal women with hormone receptor-positive advanced breast cancer that has progressed following tamoxifen therapy. Fulvestrant binds to and blocks estrogen receptors, preventing estrogens from binding and activating the receptors. This inhibits tumor growth by blocking the effects of estrogen on tumors.
1 Injection/Box:
1 Injection/Box is a new formulation of breast cancer medication, developed by AstraZeneca. It's an injectable form of fulvestrant, which is used to treat advanced hormone-sensitive breast cancer in postmenopausal women. The drug was approved in Europe and Japan in October 2015 and November 2015 respectively. It received FDA approval for the U.S on January 11th 2016 and will be launched there during the first half of 2016.
2 Injection/Box:
2 Injection/Box is a combination product of fulvestrant and estradiol used for breast cancer patients. It contains the active ingredient Fulvestrant (Fulvic Acid) which belongs to a group of drugs called as selective estrogen receptor modulators (SERM). It works by blocking the action of Estrogen in the body, thus reducing growth rate & spread of cancer cells in the breast.
Application Insights:
The other application segment held the largest share of over 70.0% in 2017. The other applications include gynecology, breast cancer, and others. Clinic is expected to be the fastest-growing application market for this drug owing to high product demand from various clinics across the world. Fulvestrant is used as a chemotherapeutic agent in treating hormone-receptor-positive breast carcinoma that has spread to other parts of the body or cannot be treated with surgery alone. It is also used for second primary tumors that have recurred after complete response following first line therapy with tamoxifen citrate or tenofovir disoproxil fumarate among others.
Breast cancer was observed as one of the major segments driving growth in Asia Pacific due to increasing prevalence rates coupled with rising awareness about early detection.
Regional Analysis:
North America was the largest regional market in 2017 owing to high product demand. The region is expected to maintain its dominance over the forecast period due to increasing cases of breast cancer and favorable government initiatives. For instance, in May 2018, Global Breast Cancer Awareness Month (GBCA), North America Fulvestrant Market Association launched a new awareness campaign with an aim to increase awareness about breast cancer among women across the globe. This initiative includes distribution of free fulvestrant tablets through health professionals’ offices and clinics along with social media campaigns such as Facebook posts and Tweets on Twitter & Instagram handles.
Asia Pacific is anticipated to be one of the fastest-growing regions during the forecast period owing rising healthcare expenditure levels coupled with improving infrastructure in emerging countries such as China & India which are major consumers for this drug product category.
Growth Factors:
- Increasing incidence of breast cancer: The incidence of breast cancer is increasing at a rapid pace across the globe. This is primarily attributed to changing lifestyle and dietary habits, growing population, and aging population. According to the American Cancer Society, around 252,710 new cases of invasive breast cancer are expected to be diagnosed in women in 2017 in the U.S., and around 40,610 women are expected to die from this disease. This is indicative of the high unmet need for better treatment options for breast cancer patients. Fulvestrant offers an improved treatment option over existing therapies and is likely to gain traction as a result.
- Growing awareness about advanced therapies for treating breast cancer: There has been a growing awareness among patients and healthcare professionals about advanced therapies available for treating various types of cancers including Breast Cancer .This has led to an increased uptake of such therapies by patients across the globe .Fulvestrant being one such therapy is likely benefit from this trend .
Scope Of The Report
Report Attributes
Report Details
Report Title
Fulvestrant Market Research Report
By Type
1 Injection/Box, 2 Injection/Box
By Application
Hospital, Clinic, Drug Center, Other
By Companies
Teva, Amneal Pharms, AstraZeneca, Novartis, Intas Pharmaceuticals, Chemo, Accure Labs, Natco
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
247
Number of Tables & Figures
173
Customization Available
Yes, the report can be customized as per your need.
Global Fulvestrant Market Report Segments:
The global Fulvestrant market is segmented on the basis of:
Types
1 Injection/Box, 2 Injection/Box
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Clinic, Drug Center, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Teva
- Amneal Pharms
- AstraZeneca
- Novartis
- Intas Pharmaceuticals
- Chemo
- Accure Labs
- Natco
Highlights of The Fulvestrant Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- 1 Injection/Box
- 2 Injection/Box
- By Application:
- Hospital
- Clinic
- Drug Center
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Fulvestrant Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Fulvestrant is a drug used to treat breast cancer. It works by blocking the growth of new tumors and reducing the size of existing tumors. Fulvestrant may also help to prevent other cancers from developing in the future.
Some of the major companies in the fulvestrant market are Teva, Amneal Pharms, AstraZeneca, Novartis, Intas Pharmaceuticals, Chemo, Accure Labs, Natco.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Fulvestrant Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Fulvestrant Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Fulvestrant Market - Supply Chain
4.5. Global Fulvestrant Market Forecast
4.5.1. Fulvestrant Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Fulvestrant Market Size (000 Units) and Y-o-Y Growth
4.5.3. Fulvestrant Market Absolute $ Opportunity
5. Global Fulvestrant Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Fulvestrant Market Size and Volume Forecast by Type
5.3.1. 1 Injection/Box
5.3.2. 2 Injection/Box
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Fulvestrant Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Fulvestrant Market Size and Volume Forecast by Application
6.3.1. Hospital
6.3.2. Clinic
6.3.3. Drug Center
6.3.4. Other
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Fulvestrant Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Fulvestrant Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Fulvestrant Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Fulvestrant Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Fulvestrant Demand Share Forecast, 2019-2026
9. North America Fulvestrant Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Fulvestrant Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Fulvestrant Market Size and Volume Forecast by Application
9.4.1. Hospital
9.4.2. Clinic
9.4.3. Drug Center
9.4.4. Other
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Fulvestrant Market Size and Volume Forecast by Type
9.7.1. 1 Injection/Box
9.7.2. 2 Injection/Box
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Fulvestrant Demand Share Forecast, 2019-2026
10. Latin America Fulvestrant Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Fulvestrant Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Fulvestrant Market Size and Volume Forecast by Application
10.4.1. Hospital
10.4.2. Clinic
10.4.3. Drug Center
10.4.4. Other
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Fulvestrant Market Size and Volume Forecast by Type
10.7.1. 1 Injection/Box
10.7.2. 2 Injection/Box
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Fulvestrant Demand Share Forecast, 2019-2026
11. Europe Fulvestrant Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Fulvestrant Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Fulvestrant Market Size and Volume Forecast by Application
11.4.1. Hospital
11.4.2. Clinic
11.4.3. Drug Center
11.4.4. Other
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Fulvestrant Market Size and Volume Forecast by Type
11.7.1. 1 Injection/Box
11.7.2. 2 Injection/Box
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Fulvestrant Demand Share, 2019-2026
12. Asia Pacific Fulvestrant Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Fulvestrant Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Fulvestrant Market Size and Volume Forecast by Application
12.4.1. Hospital
12.4.2. Clinic
12.4.3. Drug Center
12.4.4. Other
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Fulvestrant Market Size and Volume Forecast by Type
12.7.1. 1 Injection/Box
12.7.2. 2 Injection/Box
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Fulvestrant Demand Share, 2019-2026
13. Middle East & Africa Fulvestrant Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Fulvestrant Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Fulvestrant Market Size and Volume Forecast by Application
13.4.1. Hospital
13.4.2. Clinic
13.4.3. Drug Center
13.4.4. Other
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Fulvestrant Market Size and Volume Forecast by Type
13.7.1. 1 Injection/Box
13.7.2. 2 Injection/Box
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Fulvestrant Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Fulvestrant Market: Market Share Analysis
14.2. Fulvestrant Distributors and Customers
14.3. Fulvestrant Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Teva
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Amneal Pharms
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. AstraZeneca
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Novartis
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Intas Pharmaceuticals
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Chemo
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Accure Labs
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Natco
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. COMPANY9
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. COMPANY 10
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook